A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

This valuation suggests that the market may be underestimating Biogen's potential, particularly if the company can achieve sales inflections or positive pipeline developments. Biogen's product ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

Furthermore, Biogen’s efforts in pipeline diversification, particularly in immunology and inflammatory treatments, bolster its future growth potential. The recent positive data update from the ...

Biogen Inc. (NASDAQ:BIIB), a leading biotechnology company specializing in neurological treatments, finds itself at a critical juncture as it navigates the launch of its highly anticipated Alzheimer's ...

Some of these savings will be put back into Biogen’s product launches and pipeline. Biogen’s cost-cutting measures have included layoffs. Back in July 2023, Biogen said it would cut another ...

This valuation suggests that the market may be underestimating Biogen's potential, particularly if the company can achieve sales inflections or positive pipeline developments. Biogen's product ...